Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Filings indexed 417 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a press release announcing Revive Therapeutics’ strategic expansion of its bucillamine program, including preclinical studies, patent grants, and partnership plans. It contains forward-looking statements and corporate strategy details but no substantive financial results, no regulatory certification, and no formal report attachment. It does not fit any specific category like earnings release, annual or interim report, or M&A. Therefore it falls into the fallback category for general regulatory and corporate announcements.
2026-05-20 English
News release - English.pdf
Regulatory Filings
2026-03-11 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2026-02-28 English
Interim MD&A - English.pdf
Regulatory Filings
2026-02-28 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-02-28 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Revive Therapeutics providing an update on a research study regarding Bucillamine. It does not fit into specific categories like financial reports, dividend announcements, or board changes. As it is a general corporate announcement regarding operational progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-12-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.